Cancer Clinical Trials and Research Programs
Doylestown Health's Cancer Institute is a member of the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers. ECOG is funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Doylestown Health conducts research and clinical trials in collaboration with Jefferson’s Sidney Kimmel Cancer Network. Our cancer care team is proud to offer local patients the most current opportunities and the convenience of participating in these vitally important cancer research programs close to home.
Peggy Hughes, RN, BSN, OCN
Clinical Trial Nurse Coordinator
Doylestown Health is currently enrolling patients in the following approved oncology protocols:
- Phase III Randomized Trial
- Breast Cancer Weight Loss Study (BWEL Study)
- Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
- A randomized phase III trial of adjuvant chemotherapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node negative, triple negative invasive breast cancer.
- Dual Anti-CTLA4 and Anti-PD-1 Blockade in rare tumors for patient who have completed MATCH. (Combination Opdivo plus Yervoy).
- A non-therapeutic international registry to describe the practice patterns of therapeutic agents for advance prostate cancer, to identify associations between treatment sequences or combinations and overall survival, to define the patient experience and identify unmet needs in their treatment, and to identify clinical and molecular disease subtypes that predict response to individual treatments, combinations or sequences.
For more information about Doylestown Health's open cancer trials visit the U.S. National Institutes of Health's Clinical Trials database.